Geron Corporation - Special Call Transcript
Ladies and gentlemen, thank you for standing by and welcome to Geron's Key Opinion Leader Conference Call. (Operator Instructions) I would now like to hand the conference over to your moderator for today, Suzanne Messere, Head of Investor Relations. Ms. Messere, please go ahead.
Thanks, Jack. Welcome to Geron's KOL event to discuss recent data presented at the virtual edition of the 25th Annual European Hematology Annual Congress.
I am joined today by Geron's Chief Medical Officer, Dr. Aleksandra Rizo; Dr. Valeria Santini; Dr. John Mascarenhas; Dr. Rami Komrokji; and Geron's Chairman and CEO, Dr. John Scarlett. Before we begin, please note that this presentation and question-and-answer session will contain forward-looking statements relating to Geron's plans, expectations, time lines, beliefs, statements of potentiality and projections. These include, without limitation, those regarding that imetelstat has potential disease-modifying activity and that Geron has a plan to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |